Amgen Ventures
Amgen Ventures is a venture capital investment arm of Amgen Inc. specializing in investments in early and later stage companies. The firm primarily invests in the biotechnology sector with a focus on discovering and developing human therapeutics with a focus on oncology, inflammation, hematology, nephrology, metabolic disorders, neuroscience, and cardiovascular therapeutics. In oncology and hematology it focuses on novel therapeutics including signal transduction, cell cycle, and apoptosis; hematopoiesis including anemia, neutropenia, and stem cell mobilization; and supportive care including mucositis and cachexia. In nephrology the firm focuses on renal failure and hyperparathyroidism. For inflammation the firm focuses on rheumatoid arthritis, psoriasis, systemic lupus erythematosus, inflammatory bowel disease, multiple sclerosis, asthma and COPD, and osteoarthritis. Under cardiovascular, it focuses on acute coronary syndromes, dyslipidemia, and heart failure and under metabolic disorders it focuses on diabetes, metabolic syndrome, and osteoporosis. The focus on neuroscience included pain including neuropathic and inflammatory, alzheimer's disease, parkinson's disease, sleep disorder, cognition, and schizophrenia. In discovery research and technology the firm focuses on early-stage drug discovery collaborations, innovative chemical entity collections, diagnostics and biomarkers, novel antibody platforms, assay biologicals and devices, and target-focused structural biology and computational tools. It primarily invests in the North America, Europe, and the United Kingdom. The firm typically invests between $2 million and $3 million per transaction and may invest up to $10 million per company. It prefers to have an ownership stake of less than 15 % in its portfolio companies. Amgen Ventures was founded in 2004 and is based in San Francisco, California with additional offices in Seattle, Washington; Thousand Oaks, California; and Cambridge, Massachusetts.
Sector
96 past transactions
Miragen Therapeutics
Series C in 2015
MiRagen is a biopharmaceutical company that discovers and develops innovative microRNA-targeting therapies to improve human health, specifically in disease areas of high unmet medical need.
The company leverages in-house expertise in miRNA biology, oligonucleotide chemistry, and drug development to evaluate and advance best-in-class technologies and high-potential drug candidates for its own pipeline or in conjunction with strategic partners.
The company was founded in 2007 and headquartered in Boulder, Colorado.
Gandeeva Therapeutics
Series A in 2022
BigHat Biosciences
Series B in 2022
BigHat is a developer of an AI-guided protein therapeutic platform used to integrate antibody characterization lab with machine learning technologies to engineer molecules with more complex functions and better biophysical properties. The company is applying these design capabilities to develop new generations of safer and more effective treatments for patients suffering from today’s most challenging diseases.
Senti Biosciences, Inc.
Series B in 2021
Senti Biosciences is a team of bioengineers, scientists, and entrepreneurs on a mission to treat the most complex and challenging diseases. Led by pioneers in synthetic biology and computation, Senti is using the latest techniques in the fields to build the future of gene and cell-based therapies. Senti’s proprietary synthetic biology platform provides fundamental advantages for therapeutics development. Senti Biosciences is a resident company of Johnson & Johnson Innovation, JLABS at South San Francisco (JLABS @ SSF).
NAVAN Technologies, Inc.
Seed Round in 2019
NAVAN Technologies, Inc., a pre-clinical stage biotechnology company, develops and commercializes NanoStraw platform technology to enable cell and gene therapies. Its NanoStraws platform provide direct access to the cytosol of a cell to enable the delivery of any cargo into any cell in a gentle, non-perturbative manner. The company was founded in 2016 and is based in South San Francisco, California.
Surface Oncology, Inc.
Series A in 2015
Surface Oncology was created to advance next-generation approaches to cancer immunotherapy based on proprietary insights about novel immunotherapy targets and emerging areas of cancer immuno-biology. Together with world-leading scientific founders, the Company is advancing multiple preclinical programs that target novel mechanisms shown to play vital roles in tumor immune-evasion. Surface is based in Cambridge, Mass.
GPB Scientific, LLC
Venture Round in 2021
GPB Scientific, LLC develops a liquid biopsy platform for obtaining rare circulating tumor cells at their viable state from the patient's blood. It offers a desktop fluidic system for cell separation that pumps blood through a disposable microchip. The company’s fluidic system processes a tube of whole blood to remove and separate red cells and normal white cells, resulting in a viable population of rare tumor cells. GPB Scientific, LLC was incorporated in 2002 and is based in Richmond, Virginia.
Carmot Therapeutics
Series C in 2020
Carmot Therapeutics, Inc., a clinical-stage biotechnology company, discovers and develops therapies for patients with metabolic diseases. It applies Chemotype Evolution, a transformative drug discovery approach to explore novel frontiers of chemistry and biology. The company develops a portfolio of drug candidates in metabolic disease and oncology such as GLP-1R and dual GLP-1R/GIPR modulators and peptide-small molecule hybrid compounds that modulate the activity of the receptors for GLP-1 and GIP to enhance glucose clearance and weight loss to treat diabetes, obesity, NASH, and other diseases. Carmot Therapeutics, Inc. was founded in 2008 and is based in Berkeley, California with an additional office in San Francisco, California.
Kernal Biologics
Series A in 2022
Kernal Biologics, Inc. designs and develops mRNA immunotherapies. It develops mRNA immunotherapies for covid-19 and cancers. The company’s mRNA platform is used by researchers and companies working on vaccines and therapeutics for COVID-19. Kernal Biologics, Inc. was founded in 2016 and is headquartered in Cambridge, Massachusetts.
Precision BioSciences, Inc.
Series A in 2015
Precision BioSciences is a biotechnology company dedicated to improving lives through its next-generation gene editing technology, ARCUS.
Precision BioSciences’ mission is to translate the world’s most powerful genome editing technology into greatly needed products throughout the life sciences. Precision’s proprietary ARCUS genome editing technology enables the production of highly specific nucleases that can insert, remove, and modify DNA at essentially any location in a complex genome.
Catena Biosciences
Pre Seed Round in 2021
Catena Biosciences is a biotech startup based on research from UC Berkeley focusing on the treatment and cure of autoimmune disorders. Catena’s platform is based on the ability to fuse proteins together using enzyme activation of native amino acids to create new treatments in oncology, autoimmune disorders and vaccine development!
Senti Biosciences, Inc.
Post in 2022
Senti Biosciences is a team of bioengineers, scientists, and entrepreneurs on a mission to treat the most complex and challenging diseases. Led by pioneers in synthetic biology and computation, Senti is using the latest techniques in the fields to build the future of gene and cell-based therapies. Senti’s proprietary synthetic biology platform provides fundamental advantages for therapeutics development. Senti Biosciences is a resident company of Johnson & Johnson Innovation, JLABS at South San Francisco (JLABS @ SSF).
Rheostat Therapeutics
Series A in 2018
Rheostat’s mission is to invent novel treatments for neurodegenerative disease through modulation of mitophagy and autophagy. They believe that the degradation of toxic cellular components, whether they are damaged organelles or aggregated proteins, is a fundamental node of biology. Mutations that impair these clearance pathways cause multiple neurodegenerative diseases, many of which are associated with cognitive impairment. They aim to leverage our understanding of these critical pathways to discover and develop novel small molecules that will restore cellular balance and treat neurodegenerative and rare diseases.
GNS Healthcare
Venture Round in 2017
GNS Healthcare is a big data analytics company that focuses on discovering what works in the healthcare industry and for whom. They focus on advancing and applying industrial-scale data analytics to empower key healthcare stakeholders to solve complex care, treatment, and cost challenges.
It was founded in 2000 and headquartered in Cambridge, Massachusetts.
Senti Biosciences, Inc.
Series A in 2018
Senti Biosciences is a team of bioengineers, scientists, and entrepreneurs on a mission to treat the most complex and challenging diseases. Led by pioneers in synthetic biology and computation, Senti is using the latest techniques in the fields to build the future of gene and cell-based therapies. Senti’s proprietary synthetic biology platform provides fundamental advantages for therapeutics development. Senti Biosciences is a resident company of Johnson & Johnson Innovation, JLABS at South San Francisco (JLABS @ SSF).
QurAlis
Series A in 2020
QurAlis Corporation discovers and develops therapeutics for the treatment of amyotrophic lateral sclerosis (ALS) and other neurological diseases. The company’s pipeline includes treatments for subtypes of ALS, such as a drug to restore a dysfunctional cellular waste clearance system that poisons neurons; a therapy to treat overactive neurons and prevents resulting cell death; and an approach to remove toxic proteins. The company was incorporated in 2016 and is based in Cambridge, Massachusetts. QurAlis Corporation operates as a subsidiary of Q-State Biosciences, Inc.
CancerIQ
Series B in 2022
CancerIQ’s technology enables hospitals to identify, evaluate and manage entire patient populations based on individual genetic risk factors. By analyzing family history, running predictive risk models and automating NCCN guidelines, CancerIQ empowers community-based providers with the genetic expertise to prevent cancer or catch it early. The platform has been rapidly adopted by some of the top health systems in the country and fully integrates with genetics laboratories, EHRs, and specialty software vendors to streamline workflow, guide clinician decision making, achieve cost savings, and – most importantly – improve patient outcomes. Learn more about how CancerIQ is scaling the use of genetic testing to predict, preempt and prevent disease at canceriq.com.
Atara Biotherapeutics
Series B in 2013
Atara Biotherapeutics, Inc. (@Atarabio) is an off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune, and viral diseases. Atara’s technology platform leverages research collaborations with leading academic institutions with the Company’s scientific, clinical, regulatory, and manufacturing expertise. Atara’s pipeline includes tab-cel® (tabelecleucel), which is in Phase 3 development for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disorder (EBV+ PTLD) as well as in earlier stage development for other EBV-associated hematologic malignancies and solid tumors, including nasopharyngeal carcinoma (NPC); T-cell immunotherapies targeting EBV antigens believed to be important for the potential treatment of multiple sclerosis; and next-generation chimeric antigen receptor T-cell (CAR T) immunotherapies. The company was founded in 2012 and is co-located in South San Francisco and Southern California. Our Southern California hub is anchored by the state-of-the-art Atara T-cell Operations and Manufacturing (ATOM) facility in Thousand Oaks, California. For additional information about the company, please visit atarabio.com.
Miragen Therapeutics
Series B in 2015
MiRagen is a biopharmaceutical company that discovers and develops innovative microRNA-targeting therapies to improve human health, specifically in disease areas of high unmet medical need.
The company leverages in-house expertise in miRNA biology, oligonucleotide chemistry, and drug development to evaluate and advance best-in-class technologies and high-potential drug candidates for its own pipeline or in conjunction with strategic partners.
The company was founded in 2007 and headquartered in Boulder, Colorado.
Epizyme, Inc.
Series B in 2009
Epizyme is a biopharmaceutical company located in Cambridge, MA, that is focused on researching treatments for blood cancer and tumors.
Founded in late 2007, the company has brought together premier academic and industry leaders to rapidly translate the exciting discoveries emerging from epigenetic research into specific programs that will produce important, novel, molecularly targeted drugs of the future.
Miragen Therapeutics
Series B in 2012
MiRagen is a biopharmaceutical company that discovers and develops innovative microRNA-targeting therapies to improve human health, specifically in disease areas of high unmet medical need.
The company leverages in-house expertise in miRNA biology, oligonucleotide chemistry, and drug development to evaluate and advance best-in-class technologies and high-potential drug candidates for its own pipeline or in conjunction with strategic partners.
The company was founded in 2007 and headquartered in Boulder, Colorado.
Celsius Therapeutics, Inc.
Series B in 2022
Celsius Therapeutics, Inc. develops and researches drugs. The company publishes researches topics, such as single-cell genomic analysis to develop life-changing medicines. Celsius Therapeutics, Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
Theraclone Sciences, Inc.
Venture Round in 2011
Theraclone Sciences (formerly Spaltudaq) is a Seattle-based discovery-stage biotech focused on the development of novel therapeutic antibodies for the treatment of infectious disease and inflammation. The company's technology harnesses the power of the human immune system to identify naturally evolved monoclonal antibodies from the blood cells of immunologically relevant human subjects. Recombinant human monoclonal antibodies can be rapidly obtained using our discovery platform and scaled for large-scale industrial production. Such antibody drug candidates may be uniquely important in combating disease and may have potential as therapeutic products that can be administered to a broad patient population. Theraclone is a privately held company with venture investment from ARCH Venture Partners, Canaan Partners, Healthcare Ventures, Amgen Ventures, MPM Capital, and Alexandria Real Estate Investment.
Allozyne, Inc.
Series B in 2007
Allozyne develops and commercializes technologies that enable improvements in the efficacy, safety, dosing, and other characteristics of protein-based therapeutics, including peptides, antibodies, and vaccines. Its PEGylated IFN beta is for the treatment of multiple sclerosis. The company was founded in 2005 and is based in Seattle, Washington.
TetraLogic Pharmaceuticals
Series C in 2011
TetraLogic Pharmaceuticals is a privately held biopharmaceutical company that discovers and develops small molecule drugs that modulate programmed cell death pathways to treat debilitating diseases and conditions. The company's Smac Mimetics neutralize critical blocks in the apoptosis pathway to selectively destroy cancer cells. Its Necrostatin drugs block critical steps in the process leading to necrosis, enabling cell survival in a wide range of diseases and injuries where necrosis is a critical component of pathology.
Kymera Therapeutics
Series A in 2017
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing IRAK4 program for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.
ReCode Therapeutics
Series B in 2022
ReCode Therapeutics is a development-stage biopharmaceutical company focused on the correction of the nonsense mutations that account for 1/3 of all inherited diseases, including approximately 10% of cystic fibrosis. They have combined selected tRNAs with their unique and diverse proprietary delivery platforms to create and develop first-in-class suppressor tRNA-nanoparticle therapeutics for correcting nonsense mutations.
ReCode’s diverse pipeline includes lead programs for primary ciliary dyskinesia (PCD) and nonsense mutations in cystic fibrosis (CF). The company’s proprietary non-viral lipid nanoparticle platform enables the delivery of a variety of payloads, and precise organ targeting of nucleic acid and protein payloads via both systemic and local delivery. ReCode is leveraging its nanoparticle and nucleic acid technologies across multiple modalities, including mRNA-mediated protein replacement therapies, first-in-class tRNA NanoCorrectors for diseases caused by nonsense mutations, and gene editing.
The company was founded in 2015 and is based in Dallas, Texas.
TetraLogic Pharmaceuticals
Series B in 2006
TetraLogic Pharmaceuticals is a privately held biopharmaceutical company that discovers and develops small molecule drugs that modulate programmed cell death pathways to treat debilitating diseases and conditions. The company's Smac Mimetics neutralize critical blocks in the apoptosis pathway to selectively destroy cancer cells. Its Necrostatin drugs block critical steps in the process leading to necrosis, enabling cell survival in a wide range of diseases and injuries where necrosis is a critical component of pathology.
NoviSci
Seed Round in 2021
NoviSci improve the health and well-being of people through principled data science.
TileDB
Venture Round in 2022
TileDB, Inc. develops and maintains TileDB, a system for managing multi-dimensional array data that arise from scientific applications. Its products include TileDB Embedded, a storage engine; and TileDB Cloud, a storage engine that allows managing arrays data. It provides a data engine that allows people to access, analyze, and share any complex data with any tool. The system allows for the management of scientific data and allows programmers to write applications for parallel data analytics. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. It has an additional location in Athens, Greece.
Science 37
Series C in 2017
Science 37 is making the promise of virtual trials the new reality. By engaging with patients from the comfort of their own home, the company provides access to patients who can never be reached by traditional site-based research models. Its virtual model has proven to enroll faster, retain patients at a higher rate, and reach a more representative patient population. Science 37 has conducted more virtual (or decentralized), interventional trials than any other company, using an expansive, in-house network of telemedicine investigators and home-health nurses. The company's research is powered by the industry’s most comprehensive, fully integrated clinical trial platform purpose-built to conduct virtual trials.
Sutro Biopharma, Inc.
Series D in 2013
Sutro Biopharma is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
Theraclone Sciences, Inc.
Series B in 2007
Theraclone Sciences (formerly Spaltudaq) is a Seattle-based discovery-stage biotech focused on the development of novel therapeutic antibodies for the treatment of infectious disease and inflammation. The company's technology harnesses the power of the human immune system to identify naturally evolved monoclonal antibodies from the blood cells of immunologically relevant human subjects. Recombinant human monoclonal antibodies can be rapidly obtained using our discovery platform and scaled for large-scale industrial production. Such antibody drug candidates may be uniquely important in combating disease and may have potential as therapeutic products that can be administered to a broad patient population. Theraclone is a privately held company with venture investment from ARCH Venture Partners, Canaan Partners, Healthcare Ventures, Amgen Ventures, MPM Capital, and Alexandria Real Estate Investment.
DJS Antibodies Ltd
Venture Round in 2020
DJS Antibodies is discovering game-changing medicines to address recognised unmet medical need.
Discovering new medicines is extremely difficult and most traditional methods fail. They have a breakthrough technology which overcomes this hurdle – revolutionising drug development. Early work, funded by Johnson&Johnson, has shown an unprecedented success rate in discovering lead antibodies and has lead to the development of lead programmes in both cancer and kidney disease.
Obsidian Therapeutics, Inc.
Series A in 2017
Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy to every patient with cancer.The company's next-generation cell and gene therapies with pharmacologic operating systems provide exquisite control of protein activity in cells and create adoptive cell therapies with new functions that are under control of the treating physician using simple, safe, orally-active, marketed drugs, enabling patients to improve on the current generation of cell therapies.
Nkarta, Inc.
Series B in 2019
Nkarta, Inc., a biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company’s approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its co-lead product candidates are NKX101, a pre-clinical product that enhances the power of innate NK biology to detect and kill cancerous cells; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded in 2015 and is headquartered in South San Francisco, California.
Calistoga Pharmaceuticals
Series C in 2010
Calistoga Pharmaceuticals, Inc. is the leader in developing innovative oral medicines targeting selected isoforms of the PI3 kinase pathway to improve the health of patients with cancer and inflammatory diseases.
The PI3K pathway is a critical cellular pathway involved in cell survival and immune cell activation. Calistoga Pharmaceuticals' small-molecule therapeutic candidates inhibit specific isoforms of the PI3K pathway, providing a targeted treatment approach designed to maximize clinical outcome and limit unwanted side effects.
Calistoga Pharmaceuticals' lead product, CAL-101, an oral delta-isoform selective PI3K inhibitor, has demonstrated promising clinical responses in patients with B-cell malignancies and is currently being evaluated in multiple clinical trials. In addition to CAL-101, Calistoga Pharmaceuticals' product development pipeline includes other selective PI3K inhibitors in early preclinical development or ready for initial clinical trials in patients with cancer or inflammatory diseases.
Trinity Biosystems
Debt Financing in 2009
Trinity Biosystems, Inc. engages in the development and formulation of oral therapeutic proteins. It involves in developing vaccines in the areas of respiratory, digestive, and sexually transmitted diseases, as well as transporting proteins, peptides, and other macromolecules. The company was founded in 2002 and is based in Menlo Park, California.
Argolyn Bioscience
Series A in 2007
Argolyn Bioscience is a biotechnology company that develops peptide drug candidates to treat serious diseases and disorders. The company’s products are based on amino acid analog substitution technology. The company's products include ABS201 for schizophrenia and ABS212 for pain.
Oncofactor Corporation
Series A in 2011
Oncofactor is a Seattle, Washington-based developer of cancer therapeutics that disrupt signaling pathways between tumors and the immune system.
QurAlis
Seed Round in 2018
QurAlis Corporation discovers and develops therapeutics for the treatment of amyotrophic lateral sclerosis (ALS) and other neurological diseases. The company’s pipeline includes treatments for subtypes of ALS, such as a drug to restore a dysfunctional cellular waste clearance system that poisons neurons; a therapy to treat overactive neurons and prevents resulting cell death; and an approach to remove toxic proteins. The company was incorporated in 2016 and is based in Cambridge, Massachusetts. QurAlis Corporation operates as a subsidiary of Q-State Biosciences, Inc.
Sutro Biopharma, Inc.
Series C in 2012
Sutro Biopharma is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
NexImmune
Venture Round in 2014
NexImmune, Inc., a biopharmaceutical company, develops novel immuno-therapeutics based on the proprietary Artificial IMmune (AIMTM) technology. It offers AIM101, an aAPC-based injectable pharmaceutical product for the treatment of specific solid tumors; and AIM ACT, an adoptive cellular therapy to treat specific hematological malignancies. Its products are used to treat cancer, inflammation, viral diseases, transplant rejection, autoimmunity, and more. The company was founded in 2011 and is based in Gaithersburg, Maryland.
Avidia
Series C in 2006
Avidia, Inc., a biopharmaceutical company, engages in discovering and developing therapeutic proteins. The company offers Avimer therapeutic proteins, which are used to address various therapeutic areas, including autoimmunity, inflammation, oncology, and neurology. Avidia, Inc. was founded in 2003 and is headquartered in Mountain View, California.
Akili Interactive Labs
Series B in 2016
Akili builds clinically-validated cognitive therapeutics, assessments, and diagnostics that look and feel like video games. It aims to develop a new type of electronic medicine that can be deployed remotely directly to any patient anywhere, prescribed and tracked by physicians, with the potential to be developed at a fraction of the cost of traditional medical approaches.
Akili’s cognitive engine enables three separate clinical game versions for remote data-capture, with features designed for patient engagement. Its proprietary adaptive mechanics allow the software to automatically personalize to the patient’s ability level with no clinician input required.
Akili is based in Boston, Massachusetts.
TetraLogic Pharmaceuticals
Series C in 2010
TetraLogic Pharmaceuticals is a privately held biopharmaceutical company that discovers and develops small molecule drugs that modulate programmed cell death pathways to treat debilitating diseases and conditions. The company's Smac Mimetics neutralize critical blocks in the apoptosis pathway to selectively destroy cancer cells. Its Necrostatin drugs block critical steps in the process leading to necrosis, enabling cell survival in a wide range of diseases and injuries where necrosis is a critical component of pathology.
Integrated Diagnostics Inc.
Series A in 2005
The mission of Integrated Diagnostics is to leverage powerful emerging technologies in the development of diagnostic products that enable physicians and patients to manage complex and important diseases such as cancer, diabetes and Alzheimer's through blood tests that can monitor tens to hundreds of disease markers simultaneously. The company plans to develop a pipeline of game-changing diagnostic products that enable the diagnosis and prognosis of a variety of diseases. The company is based on the concept of a systems view of disease where pathophysiology arises from disease-perturbed networks of proteins, genes and other molecules.
Acylin Therapeutics
Series A in 2011
Acylin Therapeutics is the first company focused on developing inhibitors of cellular acetylation, an enzymatic mechanism fundamental to the molecular pathology of cancer, metabolic disease, and neurodegeneration. Recent discoveries by Acylin founders and other investigators have revealed protein acetylation as a cellular signal transduction regulator potentially as ubiquitous and important as phosphorylation by kinase enzymes. The Company has developed a platform technology to design specific acyltransferase inhibitors based on crystal structures, novel medicinal chemical approaches, and mechanistic understanding. Acylin has prioritized the p300 and CBP histone acetyl transferases [HATs] for initial drug discovery.
Aetion
Series B in 2019
Aetion, Inc. develops a science and analytics platform to assess real-world evidence (RWE) from a range of sources. The company offers Aetion Evidence Platform, a platform that generates RWE needed by healthcare decision makers to engage in value-based care. Its solution allows payers, providers, medical device makers, biopharma customers, and academic institutions to analyze data from various clinical and financial interactions in healthcare, including claims, electronic health records, registries, and clinical trials. The company’s platform is also used in database analytics and comparative effectiveness courses taken by epidemiologists, outcomes researchers, health economists, and biostatisticians. It serves customers worldwide. Aetion, Inc. has a strategic collaboration with McKesson. The company was founded in 2012 and is based in New York, New York.
Syapse
Series F in 2020
Syapse works with leading health systems, life sciences companies, and regulators to accelerate real-world evidence to improve the outcomes of cancer patients. By bringing these organizations together into the Syapse Learning Health Network, Syapse has built one of the world’s largest networks dedicated to improving outcomes in cancer care through improved precision medicine. Syapse and its partners are working towards a future in which all cancer patients have access to the quality of care they need.
The company was founded in 2008 and is headquartered in San Francisco, California.
Imago BioSciences, Inc.
Series A in 2014
Imago BioSciences, Inc., a biotechnology company, engages in developing medicines based on the science of genetics and epigenetics for the treatment of hematologic diseases. The company focuses on therapeutics that alter gene expression patterns. It develops medicines for hematologic diseases that result in bone marrow failure or leukemia, myelodysplastic syndrome, acute myelogenous leukemia, and other diseases. The company was incorporated in 2012 and is based in San Carlos, California.
Theraclone Sciences, Inc.
Series B in 2013
Theraclone Sciences (formerly Spaltudaq) is a Seattle-based discovery-stage biotech focused on the development of novel therapeutic antibodies for the treatment of infectious disease and inflammation. The company's technology harnesses the power of the human immune system to identify naturally evolved monoclonal antibodies from the blood cells of immunologically relevant human subjects. Recombinant human monoclonal antibodies can be rapidly obtained using our discovery platform and scaled for large-scale industrial production. Such antibody drug candidates may be uniquely important in combating disease and may have potential as therapeutic products that can be administered to a broad patient population. Theraclone is a privately held company with venture investment from ARCH Venture Partners, Canaan Partners, Healthcare Ventures, Amgen Ventures, MPM Capital, and Alexandria Real Estate Investment.
VLST Corporation
Series B in 2006
VLST Corporation is a privately held biotechnology company that has developed a novel and streamlined approach to speed the development of effective therapeutics for the treatment of inflammatory and autoimmune diseases. The VLST platform uses novel bioinformatics and state-of-the-art proteomics, to identify viral genes whose protein products function as immunomodulatory agents. The resulting product candidates will be either human homologues to these virulence factors or monoclonal antibodies that mimic the function of the virulence gene products. This approach allows for the efficient identification of high quality, pre-validated drug targets for the treatment of autoimmune and inflammatory disorders. The Company's technology has identified potential product candidates for the treatment of disorders such as multiple sclerosis, lupus, psoriasis, rheumatoid arthritis and diabetes.
Tizona Therapeutics, Inc.
Series B in 2016
The company is establishing collaborations with its scientific founders “to better understand whether regulatory T cells play a more prominent role in certain tumors,” he added. Although research suggests that Tregs cells play a more prominent role in creating immunosuppression in the microenvironment in some tumor types than others, “quite honestly, the data are lacking. One of the ways we’re going to differentiate the company is to understand that relationship better.
Theraclone Sciences, Inc.
Series A in 2006
Theraclone Sciences (formerly Spaltudaq) is a Seattle-based discovery-stage biotech focused on the development of novel therapeutic antibodies for the treatment of infectious disease and inflammation. The company's technology harnesses the power of the human immune system to identify naturally evolved monoclonal antibodies from the blood cells of immunologically relevant human subjects. Recombinant human monoclonal antibodies can be rapidly obtained using our discovery platform and scaled for large-scale industrial production. Such antibody drug candidates may be uniquely important in combating disease and may have potential as therapeutic products that can be administered to a broad patient population. Theraclone is a privately held company with venture investment from ARCH Venture Partners, Canaan Partners, Healthcare Ventures, Amgen Ventures, MPM Capital, and Alexandria Real Estate Investment.
ViaCell
Venture Round in 2004
ViaCell is a biotechnology company focused on the area of women’s health. The company develops ViaCord, which enables families preserve their baby’s umbilical cord blood at the time of birth for possible future medical use; and ViaCyte, to broaden reproductive choices for women through the cryopreservation of human unfertilized eggs.
ViaCell is based in Boston, Massachusetts.
Kymera Therapeutics
Series B in 2018
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing IRAK4 program for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.
PTC Therapeutics, Inc.
Private Equity Round in 2005
PTC Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orally administered and small-molecule drugs. It offers Ataluren, an orally administered small-molecule investigational new drug for the treatment of cystic fibrosis and duchenne muscular dystrophy caused by nonsense mutations. The company also provides PTC299, an anti-angiogenesis drug for the treatment of metastatic breast cancer, multiple tumors, and neurofibromatosis. Its products are used for the treatment of genetic disorders, oncology, and infectious diseases. PTC Therapeutics, Inc. was founded in 1998 and is based in South Plainfield, New Jersey.
Trinity Biosystems
Series B in 2006
Trinity Biosystems, Inc. engages in the development and formulation of oral therapeutic proteins. It involves in developing vaccines in the areas of respiratory, digestive, and sexually transmitted diseases, as well as transporting proteins, peptides, and other macromolecules. The company was founded in 2002 and is based in Menlo Park, California.
Avidia
Series B in 2005
Avidia, Inc., a biopharmaceutical company, engages in discovering and developing therapeutic proteins. The company offers Avimer therapeutic proteins, which are used to address various therapeutic areas, including autoimmunity, inflammation, oncology, and neurology. Avidia, Inc. was founded in 2003 and is headquartered in Mountain View, California.
Alector
Series D in 2016
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in phase II clinical trial for the treatment of frontotemporal dementia disease; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases. The company also offers AL002 and AL003, which are in phase 1b clinical trial for the treatment of Alzheimer’s disease. In addition, it has 10 programs under research and development stage. The company has a collaboration agreement with Adimab, LLC for the research and development of antibodies. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.
Allozyne, Inc.
Series A in 2005
Allozyne develops and commercializes technologies that enable improvements in the efficacy, safety, dosing, and other characteristics of protein-based therapeutics, including peptides, antibodies, and vaccines. Its PEGylated IFN beta is for the treatment of multiple sclerosis. The company was founded in 2005 and is based in Seattle, Washington.
GPB Scientific, LLC
Venture Round in 2020
GPB Scientific, LLC develops a liquid biopsy platform for obtaining rare circulating tumor cells at their viable state from the patient's blood. It offers a desktop fluidic system for cell separation that pumps blood through a disposable microchip. The company’s fluidic system processes a tube of whole blood to remove and separate red cells and normal white cells, resulting in a viable population of rare tumor cells. GPB Scientific, LLC was incorporated in 2002 and is based in Richmond, Virginia.
Fortuna Fix
Series B in 2017
Fortuna Fix inc. a clinical biotechnology company that focuses on restoring full neuronal functionality. The company operates through direct cell reprogramming technology platform (drNPC) and a proprietary bio-scaffolding technology (RMx) for the treatment of neurodegenerative diseases and neurotrauma. Additionally, the company provides programs in spinal cord Injury and Parkinson's disease The company was founded in 2015 and is based in Laval, Canada.
Calistoga Pharmaceuticals
Series A in 2008
Calistoga Pharmaceuticals, Inc. is the leader in developing innovative oral medicines targeting selected isoforms of the PI3 kinase pathway to improve the health of patients with cancer and inflammatory diseases.
The PI3K pathway is a critical cellular pathway involved in cell survival and immune cell activation. Calistoga Pharmaceuticals' small-molecule therapeutic candidates inhibit specific isoforms of the PI3K pathway, providing a targeted treatment approach designed to maximize clinical outcome and limit unwanted side effects.
Calistoga Pharmaceuticals' lead product, CAL-101, an oral delta-isoform selective PI3K inhibitor, has demonstrated promising clinical responses in patients with B-cell malignancies and is currently being evaluated in multiple clinical trials. In addition to CAL-101, Calistoga Pharmaceuticals' product development pipeline includes other selective PI3K inhibitors in early preclinical development or ready for initial clinical trials in patients with cancer or inflammatory diseases.
Syapse
Series D in 2017
Syapse works with leading health systems, life sciences companies, and regulators to accelerate real-world evidence to improve the outcomes of cancer patients. By bringing these organizations together into the Syapse Learning Health Network, Syapse has built one of the world’s largest networks dedicated to improving outcomes in cancer care through improved precision medicine. Syapse and its partners are working towards a future in which all cancer patients have access to the quality of care they need.
The company was founded in 2008 and is headquartered in San Francisco, California.
EnClear Therapies, Inc.
Series A in 2020
EnClear Therapies, Inc. develops device-based therapies for the treatment of neurodegenerative disease. The company delivers and monitors cerebrospinal fluids (CSF). The company’s therapeutic platform focuses on removing toxic proteins from the CSF. Its products are targeted for patients with Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP) and other conditions related to the central nervous system (CNS). EnClear Therapies, Inc. was incorporated in 2018 and is based in Newburyport, Massachusetts.
Tizona Therapeutics, Inc.
Series A in 2016
The company is establishing collaborations with its scientific founders “to better understand whether regulatory T cells play a more prominent role in certain tumors,” he added. Although research suggests that Tregs cells play a more prominent role in creating immunosuppression in the microenvironment in some tumor types than others, “quite honestly, the data are lacking. One of the ways we’re going to differentiate the company is to understand that relationship better.
Calistoga Pharmaceuticals
Series A in 2007
Calistoga Pharmaceuticals, Inc. is the leader in developing innovative oral medicines targeting selected isoforms of the PI3 kinase pathway to improve the health of patients with cancer and inflammatory diseases.
The PI3K pathway is a critical cellular pathway involved in cell survival and immune cell activation. Calistoga Pharmaceuticals' small-molecule therapeutic candidates inhibit specific isoforms of the PI3K pathway, providing a targeted treatment approach designed to maximize clinical outcome and limit unwanted side effects.
Calistoga Pharmaceuticals' lead product, CAL-101, an oral delta-isoform selective PI3K inhibitor, has demonstrated promising clinical responses in patients with B-cell malignancies and is currently being evaluated in multiple clinical trials. In addition to CAL-101, Calistoga Pharmaceuticals' product development pipeline includes other selective PI3K inhibitors in early preclinical development or ready for initial clinical trials in patients with cancer or inflammatory diseases.
Calistoga Pharmaceuticals
Series B in 2009
Calistoga Pharmaceuticals, Inc. is the leader in developing innovative oral medicines targeting selected isoforms of the PI3 kinase pathway to improve the health of patients with cancer and inflammatory diseases.
The PI3K pathway is a critical cellular pathway involved in cell survival and immune cell activation. Calistoga Pharmaceuticals' small-molecule therapeutic candidates inhibit specific isoforms of the PI3K pathway, providing a targeted treatment approach designed to maximize clinical outcome and limit unwanted side effects.
Calistoga Pharmaceuticals' lead product, CAL-101, an oral delta-isoform selective PI3K inhibitor, has demonstrated promising clinical responses in patients with B-cell malignancies and is currently being evaluated in multiple clinical trials. In addition to CAL-101, Calistoga Pharmaceuticals' product development pipeline includes other selective PI3K inhibitors in early preclinical development or ready for initial clinical trials in patients with cancer or inflammatory diseases.
DecImmune Therapeutics
Venture Round in 2010
DecImmune Therapeutics, Inc. develops novel peptides and antibodies for acute tissue damaging inflammation in myocardial infarction, burns, vascular injury, and reperfusion. It develops therapeutics for treating second degree burns and prevents reperfusion injury in transplant patients. DecImmune Therapeutics, Inc. was formerly known as Natural Antibodies, Inc. and changed its name to DecImmune Therapeutics, Inc. in September 2004. The company was incorporated in 2001 and is based in Cambridge, Massachusetts.
Atara Biotherapeutics
Series B in 2014
Atara Biotherapeutics, Inc. (@Atarabio) is an off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune, and viral diseases. Atara’s technology platform leverages research collaborations with leading academic institutions with the Company’s scientific, clinical, regulatory, and manufacturing expertise. Atara’s pipeline includes tab-cel® (tabelecleucel), which is in Phase 3 development for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disorder (EBV+ PTLD) as well as in earlier stage development for other EBV-associated hematologic malignancies and solid tumors, including nasopharyngeal carcinoma (NPC); T-cell immunotherapies targeting EBV antigens believed to be important for the potential treatment of multiple sclerosis; and next-generation chimeric antigen receptor T-cell (CAR T) immunotherapies. The company was founded in 2012 and is co-located in South San Francisco and Southern California. Our Southern California hub is anchored by the state-of-the-art Atara T-cell Operations and Manufacturing (ATOM) facility in Thousand Oaks, California. For additional information about the company, please visit atarabio.com.
Opsona
Series C in 2013
Drug development firm focused on immunology. They are headquartered in Dublin, Ireland.
Opsona Therapeutics is one of Europe's most innovative and dynamic drug development companies. We are at the forefront of drug development in immunology research, with particular focus on the innate immunity pathways.
Since its founding in 2004, Opsona has validated and developed a series of exciting new drug candidates and strategies which modulate the human innate immune system. We are located in Dublin, Ireland.
Ribometrix
Series A in 2018
Ribometrix is a platform therapeutics company that discovers small molecule drugs that target functional 3D RNA structures to treat human diseases.
Our scientific offices are located in the newly renovated Biolabs Space in Durham, with offices in Chapel Hill and Boston.
BeiGene
Post in 2020
BeiGene is a clinical-stage Biopharma company focused on discovering and developing innovative, best-in-class, targeted and immuno-oncology drugs that address severe unmet medical needs in a variety of cancer indications.
Genuity Science
Series B in 2017
Genuity Science is a contract genomics and data-sourcing, –analytics and –insights organization headquartered in Boston, Massachusetts, USA with offices in Dublin, Ireland and Reykjavik, Iceland. Genuity partners with global biopharma companies to offer deep end-to-end discovery services aimed at catalyzing precision health and improving the quality of life for patients around the world. Services include population-scale, disease-specific data sourcing, high-quality sequencing, robust statistical analysis and software tools for analyzing large datasets and artificial intelligence (AI). The company operates advanced CAP/CLIA genomics laboratories in Woburn, Massachusetts, USA and in Dublin, Ireland and is deeply committed to data stewardship and data governance across its global offices. For more information, see www.genuitysci.com.
Opsona
Series C in 2013
Drug development firm focused on immunology. They are headquartered in Dublin, Ireland.
Opsona Therapeutics is one of Europe's most innovative and dynamic drug development companies. We are at the forefront of drug development in immunology research, with particular focus on the innate immunity pathways.
Since its founding in 2004, Opsona has validated and developed a series of exciting new drug candidates and strategies which modulate the human innate immune system. We are located in Dublin, Ireland.
Infinity Pharmaceuticals, Inc.
Venture Round in 2004
Infinity Pharmaceuticals, Inc. engages in the discovery and development of medicines for the treatment of cancer and related conditions in the United States. Its lead product candidate includes IPI-504 (retaspimycin hydrochloride), an intravenously-administered small molecule inhibitor of heat shock protein 90 (Hsp90). The company is conducting an international Phase II clinical trial of IPI-504 in combination with Herceptin in patients with HER2-positive metastatic breast cancer; a Phase II clinical trial of IPI-504 in patients with advanced non-small cell lung cancer; and a Phase I clinical trial of IPI-504 in combination with Taxotere in patients with advanced solid tumors. Its products under Phase I clinical trial comprise IPI-493, an orally-delivered inhibitor of Hsp90, in patients with advanced solid tumors; IPI-926 for patients with advanced and/or metastatic solid tumors; and IPI-940, an orally-delivered inhibitor of fatty acid amide hydrolase for the treatment of neuropathic and inflammatory pain. Infinity Pharmaceuticals has strategic alliance agreements with Purdue Pharmaceutical Products L.P. and Mundipharma International Corporation Limited; an agreement with MedImmune, Inc. to develop and commercialize cancer drugs targeting Hsp90 and the hedgehog pathway; and a collaboration agreement with Novartis Institute for BioMedical Research, Inc. to discover, develop, and commercialize drugs targeting Bcl protein family members for the treatment of cancers.
The company is headquartered in Cambridge, Massachusetts.
Ziarco
Series B in 2014
Ziarco, Inc. develops therapeutic agents for treating inflammatory and allergic diseases. The company was founded in 2012 and is based in Palo Alto, California.
GNS Healthcare
Series D in 2019
GNS Healthcare is a big data analytics company that focuses on discovering what works in the healthcare industry and for whom. They focus on advancing and applying industrial-scale data analytics to empower key healthcare stakeholders to solve complex care, treatment, and cost challenges.
It was founded in 2000 and headquartered in Cambridge, Massachusetts.
Viron Therapeutics
Series A in 2006
Viron Therapeutics is a clinical stage biopharmaceutical company pioneering the development of viral proteins to treat and prevent human inflammatory disorders. Viral proteins represent a revolutionary new class of drugs. By harnessing the evolutionary power of viruses and other pathogens to evade the human body's protective inflammatory response, Viron is able to identify and develop powerful protein therapeutics that have distinct advantages in potency and efficacy over conventional drug therapy. Viron is the first company to successfully advance a viral protein drug into human testing.
Aetion
Series B in 2018
Aetion, Inc. develops a science and analytics platform to assess real-world evidence (RWE) from a range of sources. The company offers Aetion Evidence Platform, a platform that generates RWE needed by healthcare decision makers to engage in value-based care. Its solution allows payers, providers, medical device makers, biopharma customers, and academic institutions to analyze data from various clinical and financial interactions in healthcare, including claims, electronic health records, registries, and clinical trials. The company’s platform is also used in database analytics and comparative effectiveness courses taken by epidemiologists, outcomes researchers, health economists, and biostatisticians. It serves customers worldwide. Aetion, Inc. has a strategic collaboration with McKesson. The company was founded in 2012 and is based in New York, New York.
Gamida Cell Ltd.
Series E in 2012
Gamida Cell is dedicated to making a significant difference in the clinical practice of modern medicine by first creating, then tapping the regenerative power of therapeutic stem cells. Gamida Cell is a leader in the development of stem cell therapy technologies and products. The therapies are based on expanded populations of cord blood stem cells, for the treatment of illnesses with significant unmet clinical needs such as blood cancers, autoimmune and metabolic diseases as well as neutropenia.
Ra Pharmaceuticals
Series B in 2015
Ra Pharma is developing Cyclomimetics, a new drug class with the diversity and specificity of antibodies, coupled with the many benefits of small molecules. Ra Pharma is leveraging its ability to rapidly generate drug candidates to develop its own portfolio of products and partnerships focused on intracellular protein-protein interactions and other innovative approaches to addressing unmet medical needs.
It was founded in 2008 and headquartered in Cambridge, Massachusetts.
Accelerator Corporation
Venture Round in 2004
Founded in 2003, Accelerator Corporation is a Seattle-headquartered private equity firm with an office in New York and San Diego. The firm is focused on early-stage investments in biotechnology companies.
Theraclone Sciences, Inc.
Venture Round in 2010
Theraclone Sciences (formerly Spaltudaq) is a Seattle-based discovery-stage biotech focused on the development of novel therapeutic antibodies for the treatment of infectious disease and inflammation. The company's technology harnesses the power of the human immune system to identify naturally evolved monoclonal antibodies from the blood cells of immunologically relevant human subjects. Recombinant human monoclonal antibodies can be rapidly obtained using our discovery platform and scaled for large-scale industrial production. Such antibody drug candidates may be uniquely important in combating disease and may have potential as therapeutic products that can be administered to a broad patient population. Theraclone is a privately held company with venture investment from ARCH Venture Partners, Canaan Partners, Healthcare Ventures, Amgen Ventures, MPM Capital, and Alexandria Real Estate Investment.
Accelerator Corporation
Series C in 2007
Founded in 2003, Accelerator Corporation is a Seattle-headquartered private equity firm with an office in New York and San Diego. The firm is focused on early-stage investments in biotechnology companies.
QurAlis
Seed Round in 2018
QurAlis Corporation discovers and develops therapeutics for the treatment of amyotrophic lateral sclerosis (ALS) and other neurological diseases. The company’s pipeline includes treatments for subtypes of ALS, such as a drug to restore a dysfunctional cellular waste clearance system that poisons neurons; a therapy to treat overactive neurons and prevents resulting cell death; and an approach to remove toxic proteins. The company was incorporated in 2016 and is based in Cambridge, Massachusetts. QurAlis Corporation operates as a subsidiary of Q-State Biosciences, Inc.
InteKrin
Series C in 2008
InteKrin Therapeutics is a clinical-stage, privately held BioPharma company focused on developing and commercializing breakthrough therapeutics for neuroendocrine, metabolic, and immune disorders. Diseases such as diabetes, metabolic syndrome, and cancer are increasingly in need of novel treatments that provide patients with better treatment alternatives and help to curb soaring healthcare costs. The company is in the process of in-licensing early- and late-stage compounds that have the potential to unlock the complex hormonal relationship between metabolism, insulin resistance, and obesity.
Ardelyx, Inc.
Series B in 2011
Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of cardiorenal diseases in the United States and internationally. The company’s lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program for the treatment of patients with hyperkalemia. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.
Sutro Biopharma, Inc.
Series C in 2010
Sutro Biopharma is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
Cytos
Post in 2012
Cytos is a public biopharmaceutical company focused on the development of targeted immunotherapies with a VLP B-cell vaccines platform and ongoing preclinical development programs based on the platform.
Miragen Therapeutics
Series B in 2014
MiRagen is a biopharmaceutical company that discovers and develops innovative microRNA-targeting therapies to improve human health, specifically in disease areas of high unmet medical need.
The company leverages in-house expertise in miRNA biology, oligonucleotide chemistry, and drug development to evaluate and advance best-in-class technologies and high-potential drug candidates for its own pipeline or in conjunction with strategic partners.
The company was founded in 2007 and headquartered in Boulder, Colorado.
Akili Interactive Labs
Series C in 2018
Akili builds clinically-validated cognitive therapeutics, assessments, and diagnostics that look and feel like video games. It aims to develop a new type of electronic medicine that can be deployed remotely directly to any patient anywhere, prescribed and tracked by physicians, with the potential to be developed at a fraction of the cost of traditional medical approaches.
Akili’s cognitive engine enables three separate clinical game versions for remote data-capture, with features designed for patient engagement. Its proprietary adaptive mechanics allow the software to automatically personalize to the patient’s ability level with no clinician input required.
Akili is based in Boston, Massachusetts.
Imago BioSciences, Inc.
Series B in 2019
Imago BioSciences, Inc., a biotechnology company, engages in developing medicines based on the science of genetics and epigenetics for the treatment of hematologic diseases. The company focuses on therapeutics that alter gene expression patterns. It develops medicines for hematologic diseases that result in bone marrow failure or leukemia, myelodysplastic syndrome, acute myelogenous leukemia, and other diseases. The company was incorporated in 2012 and is based in San Carlos, California.
Miragen Therapeutics
Series A in 2009
MiRagen is a biopharmaceutical company that discovers and develops innovative microRNA-targeting therapies to improve human health, specifically in disease areas of high unmet medical need.
The company leverages in-house expertise in miRNA biology, oligonucleotide chemistry, and drug development to evaluate and advance best-in-class technologies and high-potential drug candidates for its own pipeline or in conjunction with strategic partners.
The company was founded in 2007 and headquartered in Boulder, Colorado.